(Part A) A Non-randomized, Open, Single-dose Escalation to Evaluate Tolerability and Safety of Single Oral Dose of HY209; (Part B) A Block-randomized, Double-blinded, Placebo-controlled, Multiple-dose Escalation to Evaluate Tolerability and Safety of Multiple Oral Doses of HY209 Phase 1 Clinical Trial in Healthy Volunteers
Latest Information Update: 20 Aug 2024
At a glance
- Drugs Taurodeoxycholic-acid (Primary)
- Indications Dementia
- Focus Adverse reactions; First in man
- Sponsors Kukjeon Pharmaceutical
Most Recent Events
- 06 Aug 2024 New trial record